Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study

The Lancet Oncology

Volumn 10, Issue 12, 2009, Pages 1152-1159

  Guiguet, Marguerite ^a   Boué, François ^b   Cadranel, Jacques ^c   Lang, Jean Marie ^d   Rosenthal, Eric ^e   Costagliola, Dominique ^a,f  

^a SORBONNE UNIVERSITÉ   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

^c HÔPITAL TENON   (France)

^d HÔPITAL CIVIL   (France)

^e CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ANTIVIRAL THERAPY; ANUS CANCER; ARTICLE; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COHORT ANALYSIS; DATA BASE; EARLY DIAGNOSIS; EARLY INTERVENTION; FEMALE; FOLLOW UP; FRANCE; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE DEFICIENCY; KAPOSI SARCOMA; LIVER CANCER; LUNG CANCER; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; POISSON DISTRIBUTION; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; UTERINE CERVIX CANCER; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; RISK FACTORS; VIRAL LOAD;

EID: 70649103959     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70282-7     Document Type: Article

References (34)

1. Spano J., Costagliola D., Katlama C., Mounier N., Oksenhendler E., and Khayat D. AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol 26 (2008) 4834-4842
2. Deeks S., and Phillips A. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BMJ 338 (2009) 288-292
3. Silverberg M., and Abrams D. AIDS-defining and non-AIDS-defining malignancies: cancer occurence in the antiretroviral era. Curr Opin Oncol 19 (2007) 446-451
4. Patel P., Hanson D., Sullivan P., et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med 148 (2008) 728-736
5. Engels E., Biggar R., Hall H., et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 123 (2008) 187-194
6. Crum-Cianflone N., Hullsiek K., Marconi V., et al. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study. AIDS 23 (2009) 41-50
7. Herida M., Mary-Krause M., Kaphan R., et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol 21 (2003) 3447-3453
8. Clifford G., Polesel J., Rickenbach M., et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst 16 (2005) 425-432
9. Grulich A.E., van Leeuwen M.T., Falster M.O., and Vajdic C.M. Incidence of cancers in people with HIV/AIDS compared with immunosuppressed transplant recipients: a meta-analysis. Lancet 370 (2007) 59-67
10. Grabar S., Le Moing V., Goujard C., et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 133 (2000) 401-410
11. Lanoy E., Spano J., Bonnet F., et al. AIDS and non-AIDS defining malignancies in HIV-infected patients: the 2006 ONCOVIH French study. Antivir Ther 13 suppl 4 (2008) A17
12. Burnham K., and Anderson D. Model selection and inference. A practical information-theoretic approach (1998), Springer-Verlag, New York
13. Bonnet F., Burty C., Lewden C., et al. Changes in cancer mortality among HIV-infected patients: the mortality 2005 survey. Clin Infect Dis 48 (2009) 633-639
14. Silverberg M., Chao C., Leyden W., et al. HIV infection and the risk of cancers with and without a known infectious cause. AIDS (2009) 10.1097/QAD.0b013e3283319184 published online Sept 7.
15. Piketty C., Selinger-Leneman H., Grabar S., et al. Marked increased in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. AIDS 22 (2008) 1203-1211
16. Lanoy E., Mary-Krause M., Tattevin P., et al. Frequency, determinants and consequences of delayed access to care for HIV infection in France. Antivir Ther 12 (2007) 89-96
17. Franceschi S., Polesel J., Rickenbach M., et al. Hepatitis C virus and non-Hodgkin's lymphoma: findings from the Swiss Cohort Study. Br J Cancer 95 (2006) 1598-1602
18. D:A:D Study Group. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS defining malignancies. AIDS 22 (2008) 2143-2153
19. Marin B., Thiebaut R., Bucher H., et al. Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 23 (2009) 1743-1753
20. Schulz T. Cancer and viral infections in immunocompromised indivuduals. Int J Cancer 125 (2009) 1755-1763
21. Zoufaly A., Stellbrink H., Heiden M., et al. Cumulative HIV viremia during highly active retroviral therapy is a strong predictor of AIDS-related lymphoma. J Infect Dis 200 (2009) 79-87
22. Bruyand M., Thiebaut R., Lawson-Ayayi S., et al. Role of uncontrolled HIV RNA level and immunodeficiency in the occurence of malignancy in HIV infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le SIDA (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis 49 (2009) 1109-1116
23. Dieu-Nosjean M., Antoine M., Danel C., et al. Long-term survival for patients with non-small-cell lung cancer with intratumoral lymphoid structures. J Clin Oncol 26 (2008) 4410-4417
24. Franceschi S., Dal Maso L., Rickenbach M., et al. Kaposi sarcoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapy. Br J Cancer 99 (2008) 800-804
25. Polesel J., Clifford G., Rickenbach M., et al. Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after higly active antiretroviral therapy. AIDS 22 (2008) 301-306
26. Silverberg M., Neuhaus J., Bower M., et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 21 (2007) 1957-1963
27. Di Lorenzo G., Konstantinopoulos P.A., Pantanowitz L., Di Trolio R., De Placido S., and Dezube B.J. Management of AIDS-related Kaposi's sarcoma. Lancet Oncol 8 (2007) 167-176
28. Kuller L., Tracy R., Belloso W., et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5 (2008) e203
29. Reekie J, Mocroft A, Engsig F, et al. Relationship between current level of immunodeficiency and non-AIDS defining maligancies. 16th conference on retrovirus and opportunistic infections; Montreal; Feb 8-11, 2009. Abstr 860a.
30. Biggar R., Jaffe E., Goedert J., et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 108 (2006) 3786-3791
31. Levine A. Hodgkin lymphoma: to the HAART of the matter. Blood 108 (2006) 3630
32. Cadranel J., Garfield D., Lavolé A., Wislez M., Milleron B., and Mayaud C. Lung cancer in HIV infected patients: facts, questions and challenges. Thorax 61 (2006) 1000-1008
33. Powles T., Robinson D., Stebbing J., et al. Highly active antiretroviral therapy and the incidence of non-AIDS-defining cancers in people with HIV infection. J Clin Oncol 27 (2009) 884-890
34. Palefsky J., and Holly E. Immunosuppression and co-infection with HIV. J Natl Cancer Inst Monogr 31 (2003) 41-46